Disease relevance of Sobrerol

• Sobrerol, carveol and uroterpenol are novel cancer chemopreventive agents with little or no toxicity [1].
• The present data indicate that treatment of rats with inhibitors of farnesyltransferase, like limonene and sobrerol, regulate the development of pulmonary hypertension [2].
• Pharmacokinetics of Sobrerol in chronic bronchitis. Comparison of serum and bronchial mucus levels [3].
• Sobrerol in the treatment of secretory otitis media in childhood [4].
• No demonstrable effect of sobrerol as an expectorant in patients with stable chronic bronchial diseases [5].

High impact information on Sobrerol

• Excretion of radioactivity from [3H]DMBA was doubled in rats fed 5% limonene and nearly tripled in rats fed 1% sobrerol [1].
• Five per cent limonene was more effective than 1% sobrerol at increasing the levels of members of the CYP2B and 2C families but was equally effective at increasing EH [6].
• Quantification of carvone, cineole, perillaldehyde, perillyl alcohol and sobrerol by isocratic high-performance liquid chromatography [7].
• The characterization of the solid state of sobrerol enantiomers and racemates has been accomplished by a number of techniques on solid phase such as thermal analysis (DSC) and spectroscopy (IR, 13C NMR, and X-ray diffraction both on powders and on single crystal) [8].
• The mono-beta-glucuronides of sobrerol excreted in bile undergo enterohepatic circulation [9].

Chemical compound and disease context of Sobrerol

• Effect of limonene and sobrerol on monocrotaline-induced lung alterations and pulmonary hypertension [2].

Biological context of Sobrerol

• Action of sobrerol on mucociliary transport [10].

Anatomical context of Sobrerol

• The pharmacokinetic profile of Sobrerol, a mucolytic drug, has been studied in patients with acute exacerbations of chronic bronchitis and dense sputum [3].
• Effects of sobrerol treatment on macromolecule secretion, ion and water fluxes in sheep trachea [11].

Analytical, diagnostic and therapeutic context of Sobrerol

• Side effects, which were minor and no different from those claimed by the patients treated with placebo, and the hematological and hematochemical assessments, carried out before and after treatment, support the good tolerance of sobrerol [12].
• 706 chronic bronchitic patients were admitted to a double-blind controlled multicenter study to evaluate the effect of the prolonged administration of sobrerol on exacerbations, clinical signs and respiratory function indexes [12].
• Treatment with sobrerol significantly (P less than 0.01) reduced frontal headache and rhinorrhoea, efficacy being confirmed by rhinomanometry [13].
• A randomized double-blind study comparing the effect of 7 days treatment with 800 mg daily oral sobrerol versus placebo in two groups of 10 patients each, affected by chronic bronchitis, was performed [14].
• A randomized double-blind cross-over study compared the clinical effectiveness of a 14-day treatment with 400 mg X day-1 of sobrerol and placebo in 23 patients with stable chronic bronchial disease [5].

References